BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16373329)

  • 1. Pharmacologic implications of neurobiological models of schizophrenia.
    Goff DC
    Harv Rev Psychiatry; 2005; 13(6):352-9. PubMed ID: 16373329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
    Javitt DC
    Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotics in the early stage of development.
    Biedermann F; Fleischhacker WW
    Curr Opin Psychiatry; 2009 May; 22(3):326-30. PubMed ID: 19346948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biochemical and genetic aspects of pathogenesis of schizophrenia].
    Kambarova DK; Golubev AG
    Zh Evol Biokhim Fiziol; 2011; 47(5):348-57. PubMed ID: 22145315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
    Large CH
    J Psychopharmacol; 2007 May; 21(3):283-301. PubMed ID: 17591656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Schizophrenia and glutamate transport systems].
    Nishikawa T
    Seishin Shinkeigaku Zasshi; 2009; 111(7):859-67. PubMed ID: 19999298
    [No Abstract]   [Full Text] [Related]  

  • 8. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.
    Millan MJ; Brocco M
    Therapie; 2008; 63(3):187-229. PubMed ID: 18718210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between N-methyl-D-aspartic acid receptors and D1 dopamine receptors: an important mechanism for brain plasticity.
    Scott L; Aperia A
    Neuroscience; 2009 Jan; 158(1):62-6. PubMed ID: 19000746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary: genome-based CNS drug discovery: D-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges.
    Williams M
    Biochem Pharmacol; 2009 Dec; 78(11):1360-5. PubMed ID: 19591808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decoding schizophrenia.
    Javitt DC; Coyle JT
    Sci Am; 2004 Jan; 290(1):48-55. PubMed ID: 14682038
    [No Abstract]   [Full Text] [Related]  

  • 12. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The acute effects of NMDA antagonism: from the rodent to the human brain.
    Gunduz-Bruce H
    Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New pharmacological approaches to the treatment of schizophrenia].
    Uzbay IT
    Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-based gene selection shows engrailed 1 is associated with antipsychotic response.
    Webb BT; Sullivan PF; Skelly T; van den Oord EJ
    Pharmacogenet Genomics; 2008 Sep; 18(9):751-9. PubMed ID: 18698228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations of dopamine and serotonin transmission in schizophrenia.
    Remington G
    Prog Brain Res; 2008; 172():117-40. PubMed ID: 18772030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schizophrenia.
    Morrison PD; Murray RM
    Curr Biol; 2005 Dec; 15(24):R980-4. PubMed ID: 16360673
    [No Abstract]   [Full Text] [Related]  

  • 18. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection.
    Lieberman JA; Malaspina D; Jarskog LF
    CNS Spectr; 2006 Apr; 11(4):suppl 1-13; quiz suppl 14-5. PubMed ID: 16641837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of glutamate in the pathophysiology of major depressive disorder.
    Hashimoto K
    Brain Res Rev; 2009 Oct; 61(2):105-23. PubMed ID: 19481572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiologically based treatment interventions in schizophrenia.
    Lewis DA; Gonzalez-Burgos G
    Nat Med; 2006 Sep; 12(9):1016-22. PubMed ID: 16960576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.